Source:http://linkedlifedata.com/resource/pubmed/id/10778983
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2000-8-3
|
| pubmed:abstractText |
Incubation of drug-resistant human tumor cells with a combination of prochlorperazine and dipyridamole has additive/synergistic effect on the cellular retention and cytotoxicity of doxorubicin. In patients administered a fixed dose of doxorubicin and prochlorperazine with escalating doses of dipyridamole, mean plasma levels of dipyridamole and prochlorperazine achieved were as high as 3.01 +/- 0.41 microm and 0.94 +/- 0.09 microm, respectively. Plasma samples from patients were analyzed in an in vitro assay to monitor the effect on the cellular retention of tritium-labeled daunorubicin in MDR1-transfected P388 cells. In 22 of 49 of the plasma samples analyzed, the daunorubicin in efflux blocking activity was one-half or greater than that of cells incubated with 12.5 microM verapamil, a well-known efflux blocker. These observations suggest that a combination of prochlorperazine and dipyridamole may enhance cellular doxorubicin retention by blocking efflux while reducing normal tissue toxicity and unwanted side effects in vivo.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Culture Media,
http://linkedlifedata.com/resource/pubmed/chemical/Daunorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Dipyridamole,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Prochlorperazine
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
1078-0432
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
6
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1508-17
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:10778983-Animals,
pubmed-meshheading:10778983-Antineoplastic Agents,
pubmed-meshheading:10778983-Area Under Curve,
pubmed-meshheading:10778983-Cell Survival,
pubmed-meshheading:10778983-Colonic Neoplasms,
pubmed-meshheading:10778983-Culture Media,
pubmed-meshheading:10778983-Daunorubicin,
pubmed-meshheading:10778983-Dipyridamole,
pubmed-meshheading:10778983-Dose-Response Relationship, Drug,
pubmed-meshheading:10778983-Doxorubicin,
pubmed-meshheading:10778983-Drug Resistance, Neoplasm,
pubmed-meshheading:10778983-Drug Synergism,
pubmed-meshheading:10778983-Humans,
pubmed-meshheading:10778983-Infusions, Intravenous,
pubmed-meshheading:10778983-Metabolic Clearance Rate,
pubmed-meshheading:10778983-Neoplasms,
pubmed-meshheading:10778983-Plasma,
pubmed-meshheading:10778983-Prochlorperazine,
pubmed-meshheading:10778983-Tumor Cells, Cultured
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Synergistic effect of prochlorperazine and dipyridamole on the cellular retention and cytotoxicity of doxorubicin.
|
| pubmed:affiliation |
Department of Radiation Oncology, University of Miami Medical School and Sylvester Cancer Center, Florida 33136, USA. akrishan@mednet.med.miami.edu
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|